BrightPath Biotherapeutics Co.,Ltd. (4594.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.7x

Market Cap

JPY 5.87B

MomentumView details →

1D Return

+0.00%

YTD Return

+6.25%

RSI (14)

47.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.7x

Market Cap

JPY 5.87B

RSI (14)

47.5

MomentumView details →

1D Return

+0.00%

YTD Return

+6.25%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−116.20%

ROA (TTM)

−94.58%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+4.92%

FCF YoY

—

Revenue CAGR 3Y

−59.45%

EPS CAGR 3Y

+22.46%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

7.09x

Quick Ratio

7.09x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.00M

Net Income (TTM)

−1.29B

Op. CF (TTM)

—

Next earningsNov 6, 2026 →

Latest newsMore news →

BrightPath Biophotonics announced its fiscal Q1 (April-June) results on August 14, reporting an expanded recurring loss of 540 million yen, compared with a 240 million yen loss in the same period last year.22d ago

Similar companies

NIPPON CHEMIPHAR CO.,LTD.4539.T Chiome Bioscience Inc.4583.T J-Pharma Co.,Ltd.520A.T Noile-Immune Biotech Inc.4893.T PRISM BioLab Co.,LTD206A.T Cyfuse Biomedical K.K.4892.T Find similar companies →

Latest newsMore news →

BrightPath Biophotonics announced its fiscal Q1 (April-June) results on August 14, reporting an expanded recurring loss of 540 million yen, compared with a 240 million yen loss in the same period last year.22d ago